US Patent

US12544381 — Topical formulation for JAK inhibitor

Formulation · Assigned to Incyte Corp · Expires 2031-05-20 · 5y remaining

Vulnerability score 44/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a topical formulation for the JAK inhibitor RUXOLITINIB PHOSPHATE, used in the treatment of skin disorders.

USPTO Abstract

This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: US12544381
Jurisdiction: US
Classification: Formulation
Expires: 2031-05-20
Drug substance claim: No
Drug product claim: Yes
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.